ByTrending Posts
AbbVie Invested $400 Million in AI in 2025:…
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence (AI) and data-driven…
Is Eli Lilly’s $450 Million AI Investment in…
Global – December 31, 2025 — Eli Lilly and Company significantly expanded its artificial intelligence (AI) investments in…
Is Pfizer’s $500 Million AI Investment in 2025…
Global – December 31, 2025 — Pfizer Inc. significantly increased investment in artificial intelligence (AI) across its discovery,…
Is Biopharma’s $8.5 Billion AI Investment in 2025…
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
Does BioMark’s 2025 Corporate Update Mark the Shift…
Executive Summary BioMark’s 2025 corporate update marks a decisive inflection point as the company completes a landmark lung…
Does Allarity Therapeutics’ Year-End Strategic Update Signal Renewed…
Global – December 2025 — Allarity Therapeutics (NASDAQ: ALLR) has outlined key strategic and operational progress in its…
Do Wegovy Pricing Pathways in 2026 Signal a…
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited…
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Will Axsome Therapeutics’ FDA Priority Review of AXS-05…
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Trending Posts
Latest Stories
Can Insilico Medicine and China Medical System Accelerate AI-Discovered Drugs from Algorithm to Clinic?
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China…
Can Angelini’s $120M AI Alliance with Quiver Bioscience Redefine Drug Discovery in Genetic Epilepsies?
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a…
Is Takeda’s $1.7B Bet on Iambic Therapeutics the Defining Moment for AI-Validated Drug Discovery?
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has…
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition…
Gallery
